Lisata Therapeutics is a clinical-stage pharmaceutical company developing certepetide, an investigational therapy that activates a novel C-end rule transport mechanism to enhance the delivery of anti-cancer drugs to solid tumors while sparing normal tissues. Certepetide works both by improving drug penetration into tumors and by modifying the tumor microenvironment to reduce immunosuppression and enhance immune cell activity, potentially broadening its utility across chemotherapy, immunotherapy, and other modalities. The company is evaluating certepetide primarily in pancreatic cancer and other solid tumors through multiple clinical trials, with a development strategy focused on co-administration with existing anti-cancer agents to accelerate clinical advancement and avoid the burden of discovering new chemical entities.